Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models

Neurobiology of Disease

Volumn 21, Issue 2, 2006, Pages 444-455

  Graham, Rona K ^a   Slow, Elizabeth J ^a   Deng, Yu ^a   Bissada, Nagat ^a   Lu, Ge ^a   Pearson, Jacqueline ^a   Shehadeh, Jacqueline ^a   Leavitt, Blair R ^a   Raymond, Lynn A ^a   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Behavior; Excitotoxicity; Huntington disease; Mouse model; Mutant huntingtin; Neurodegeneration; Neuropathology

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EXCITOTOXICITY; HUNTINGTON CHOREA; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

AGE OF ONSET; ANIMALS; BLOTTING, WESTERN; BRAIN; CHROMOSOMES, ARTIFICIAL, YEAST; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HOMOZYGOTE; HUNTINGTON DISEASE; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PHENOTYPE; RECEPTORS, N-METHYL-D-ASPARTATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 30744459353     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2005.08.007     Document Type: Article

References (51)

1. R.L. Albin, A.B. Young, J.B. Penney, B. Handelin, R. Balfour, K.D. Anderson, D.S. Markel, W.W. Tourtellotte, and A. Reiner Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease N. Engl. J. Med. 322 1990 1293 1298
2. S.E. Andrew, Y.P. Goldberg, B. Kremer, H. Telenius, J. Theilmann, S. Adam, E. Starr, F. Squitieri, B. Lin, M.A. Kalchman, R.K. Graham, and M.R. Hayden The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease Nat. Genet. 4 1993 398 403
3. GP. Bates, and S.W. Davies Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions Mol. Med. Today 3 1997 508 515
4. M.F. Beal, R.J. Ferrante, K.J. Swartz, and N.W. Kowall Chronic quinolinic acid lesions in rats closely resemble Huntington's disease J. Neurosci. 11 1991 1649 1659
5. M.F. Beal Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31 1992 119 130
6. R.R. Brinkman, M.M. Mezei, J. Theilmann, E. Almqvist, and M.R. Hayden The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size Am. J. Hum. Genet. 60 1997 1202 1210
7. E.N. Burright, H.T. Orr, and H.B. Clark Mouse models of human CAG repeat disorders Brain Pathol. 7 1997 965 977
8. C. Cepeda, M.A. Ariano, C.R. Calvert, J. Flores-Hernandez, S.H. Chandler, B.R. Leavitt, M.R. Hayden, and M.S. Levine NMDA receptor function in mouse models of Huntington disease J. Neurosci. Res. 66 2001 525 539
9. S.W. Davies, M. Turmaine, B.A. Cozens, M. DiFiglia, A.H. Sharp, C.A. Ross, E. Scherzinger, E.E. Wanker, L. Mangiarini, and G.P. Bates Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537 548
10. M. DiFiglia Excitotoxic injury of the neostriatum: a model for Huntington's disease Trends Neurosci. 13 1990 286 289
11. M. DiFiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, and N. Aronin Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993
12. L. Djousse, B. Knowlton, M. Hayden, E.W. Almqvist, R. Brinkman, C. Ross, R. Margolis, A. Rosenblatt, A. Durr, and C. Dode Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease Am. J. Med. Genet. 119A 2003 279 282
13. A. Durr, V. Hahn-Barma, A. Brice, C. Pecheux, C. Dode, and J. Feingold Homozygosity in Huntington's disease J. Med. Genet. 36 1999 172 173
14. R.B. Dyer, and C.T. McMurray Mutant protein in Huntington disease is resistant to proteolysis in affected brain Nat. Genet. 29 2001 270 278
15. J.F. Gusella Huntington's disease Adv. Hum. Genet. 20 1991 125 151
16. C.A. Gutekunst, S.H. Li, H. Yi, J.S. Mulroy, S. Kuemmerle, R. Jones, D. Rye, R.J. Ferrante, S.M. Hersch, and X.J. Li Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology J. Neurosci. 19 1999 2522 2534
17. V. Hahn-Barma, B. Deweer, A. Durr, C. Dode, J. Feingold, B. Pillon, Y. Agid, A. Brice, and B. Dubois Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers J. Neurol., Neurosurg. Psychiatry 64 1998 172 177
18. J.G. Hodgson, D.J. Smith, K. McCutcheon, H.B. Koide, K. Nishiyama, M.B. Dinulos, M.E. Stevens, N. Bissada, J. Nasir, I. Kanazawa, C.M. Disteche, E.M. Rubin, and M.R. Hayden Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype Hum. Mol. Genet. 5 1996 1875 1885
19. J.G. Hodgson, N. Agopyan, C.A. Gutekunst, B.R. Leavitt, F. LePiane, R. Singaraja, D.J. Smith, N. Bissada, K. McCutcheon, J. Nasir, L. Jamot, X.J. Li, M.E. Stevens, E. Rosemond, J.C. Roder, A.G. Phillips, E.M. Rubin, S.M. Hersch, and M.R. Hayden A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration Neuron 23 1999 181 192
20. Y.J. Kim, Y. Yi, E. Sapp, Y. Wang, B. Cuiffo, K.B. Kegel, Z.H. Qin, N. Aronin, and M. DiFiglia Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis Proc. Natl. Acad. Sci. U. S. A. 98 2001 12784 12789
21. G.B. Landwehrmeyer, S.M. McNeil, L.S. Dure, P. Ge, H. Aizawa, Q. Huang, C.M. Ambrose, M.P. Duyao, E.D. Bird, and E. Bonilla Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals Ann. Neurol. 37 1995 218 230
22. D.R. Langbehn, R.R. Brinkman, D. Falush, J.S. Paulsen, and M.R. Hayden A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length Clin. Genet. 65 2004 267 277
23. B.R. Leavitt, J.A. Guttman, J.G. Hodgson, G.H. Kimel, R. Singaraja, A.W. Vogl, and M.R. Hayden Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo Am. J. Hum. Genet. 68 2001 313 324
24. M.S. Levine, G.J. Klapstein, A. Koppel, E. Gruen, C. Cepeda, M.E. Vargas, E.S. Jokel, E.M. Carpenter, H. Zanjani, R.S. Hurst, A. Efstratiadis, S. Zeitlin, and M.F. Chesselet Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease J. Neurosci. Res. 58 1999 515 532
25. H. Li, S.H. Li, A.L. Cheng, L. Mangiarini, G.P. Bates, and X.J. Li Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice Hum. Mol. Genet. 8 1999 1227 1236
26. C.H. Lin, S. Tallaksen-Greene, W.M. Chien, J.A. Cearley, W.S. Jackson, A.B. Crouse, S. Ren, X.J. Li, R.L. Albin, and P.J. Detloff Neurological abnormalities in a knock-in mouse model of Huntington's disease Hum. Mol. Genet. 10 2001 137 144
27. J.B. Martin Molecular basis of the neurodegenerative disorders N. Engl. J. Med. 340 1999 1970 1980
28. R.H. Myers, J. Leavitt, L.A. Farrer, J. Jagadeesh, H. McFarlane, C.A. Mastromauro, R.J. Mark, and J.F. Gusella Homozygote for Huntington disease Am. J. Hum. Genet. 45 1989 615 618
29. Y. Narain, A. Wyttenbach, J. Rankin, R.A. Furlong, and D.C. Rubinsztein A molecular investigation of true dominance in Huntington's disease J. Med. Genet. 36 1999 739 746
30. M. Oda, H. Maruyama, O. Komure, H. Morino, H. Terasawa, Y. Izumi, T. Imamura, M. Yasuda, K. Ichikawa, M. Ogawa, M. Matsumoto, and H. Kawakami Possible reduced penetrance of expansion of 44 to 47 CAG/CAA repeats in the TATA-binding protein gene in spinocerebellar ataxia type 17 Arch. Neurol. 61 2004 209 212
31. P.H. Reddy, M. Williams, V. Charles, L. Garrett, L. Pike-Buchanan, W.O. Whetsell Jr., G. Miller, and D.A. Tagle Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA Nat. Genet. 20 1998 198 202
32. D. Rigamonti, J.H. Bauer, C. De-Fraja, L. Conti, S. Sipione, C. Sciorati, E. Clementi, A. Hackam, M.R. Hayden, Y. Li, J.K. Cooper, C.A. Ross, S. Govoni, C. Vincenz, and E. Cattaneo Wild-type huntingtin protects from apoptosis upstream of caspase-3 J. Neurosci. 20 2000 3705 3713
33. CA. Ross Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders Neuron 35 2002 819 822
34. E.J. Slow, J. Van Raamsdonk, D. Rogers, S.H. Coleman, R.K. Graham, Y. Deng, R. Oh, N. Bissada, S.M. Hossain, Y.Z. Yang, X.J. Li, E.M. Simpson, C.A. Gutekunst, B.R. Leavitt, and M.R. Hayden Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease Hum. Mol. Genet. 12 2003 1555 1567
35. J.S. Snowden, D. Craufurd, H.L. Griffiths, and D. Neary Awareness of involuntary movements in Huntington disease Arch. Neurol. 55 1998 801 805
36. F. Squitieri, G. Sabbadini, P. Mandich, C. Gellera, M.E. Di, E. Bellone, B. Castellotti, E. Nargi, G.U. de, M. Frontali, and A. Novelletto Family and molecular data for a fine analysis of age at onset in Huntington disease Am. J. Med. Genet. 95 2000 366 373
37. F. Squitieri, C. Gellera, M. Cannella, C. Mariotti, G. Cislaghi, D.C. Rubinsztein, E.W. Almqvist, D. Turner, A.C. Bachoud-Levi, S.A. Simpson, M. Delatycki, V. Maglione, M.R. Hayden, and S.D. Donato Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course Brain 126 2003 946 955
38. T.S. Tang, E. Slow, V. Lupu, I.G. Stavrovskaya, M. Sugimori, R. Llinas, B.S. Kristal, M.R. Hayden, and I. Bezprozvanny Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 102 2005 2602 2607
39. J.M. Van Raamsdonk, J. Pearson, D.A. Rogers, N. Bissada, A.W. Vogl, M.R. Hayden, and B.R. Leavitt Loss of wild type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease Hum. Mol. Genet. 14 2005 1379 1392
40. J.M. Van Raamsdonk, J. Pearson, E.J. Slow, S.M. Hossain, B.R. Leavitt, and M.R. Hayden Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease J. Neurosci. 25 2005 4169 4180
41. J.M. Warrick, H.L. Paulson, Gray-Board, Q.T. Bui, K.H. Fischbeck, R.N. Pittman, and N.M. Bonini Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila Cell 93 1998 939 949
42. C.L. Wellington, L.M. Ellerby, A.S. Hackam, R.L. Margolis, M.A. Trifiro, R. Singaraja, K. McCutcheoon, G.S. Salvesen, S.S. Propp, and M. Bromm Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract J. Biol. Chem. 273 1998 9158 9167
43. C.L. Wellington, R. Singaraja, L. Ellerby, J. Savill, S. Roy, B. Leavitt, E. Cattaneo, A. Hackam, A. Sharp, N. Thornberry, D.W. Nicholson, D.E. Bredesen, and M.R. Hayden Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells J. Biol. Chem. 275 2000 19831 19838
44. N.S. Wexler, A.B. Young, R.E. Tanzi, H. Travers, S. Starosta-Rubinstein, J.B. Penney, S.R. Snodgrass, I. Shoulson, F. Gomez, Ramos, and M.A. Arroyo Homozygotes for Huntington's disease Nature 326 1987 94 97
45. V.C. Wheeler, C.A. Gutekunst, V. Vrbanac, L.A. Lebel, G. Schilling, S. Hersch, R.M. Friedlander, J.F. Gusella, J.P. Vonsattel, D.R. Borchelt, and M.E. MacDonald Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice Hum. Mol. Genet. 11 2002 633 640
46. A.B. Young Impairment of energy metabolism and excitotoxic cell death in Huntington disease Rev. Neurol. (Paris) 153 1997 496 498
47. A.B. Young, J.T. Greenamyre, Z. Hollingsworth, R. Albin, C. D'Amato, I. Shoulson, and J.B. Penney NMDA receptor losses in putamen from patients with Huntington's disease Science 241 1988 981 983
48. M.M. Zeron, O. Hansson, N. Chen, C.L. Wellington, B.R. Leavitt, P. Brundin, M.R. Hayden, and L.A. Raymond Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease Neuron 33 2002 849 860
49. M.M. Zeron, H.B. Fernandes, C. Krebs, J. Shehadeh, C.L. Wellington, B.R. Leavitt, K.G. Baimbridge, M.R. Hayden, and L.A. Raymond Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease Mol. Cell. Neurosci. 25 2004 469 479
50. Y. Zhang, M. Li, M. Drozda, M. Chen, S. Ren, R.O. Mejia Sanchez, B.R. Leavitt, E. Cattaneo, R.J. Ferrante, M.R. Hayden, and R.M. Friedlander Depletion of wild-type huntingtin in mouse models of neurologic diseases J. Neurochem. 87 2003 101 106
51. J. Zlotogora Dominance and homozygosity Am. J. Med. Genet. 68 1997 412 416